Satsuma Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a STSA research report →
About the company
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies for the rapid relief of migraines. Its lead therapeutic candidate, STS101, is an integrated drug-device system comprising a proprietary dry-powder formulation of dihydroergotamine mesylate.
- CEO
- John A. Kollins MBA
- IPO
- 2019
- Employees
- 25
- HQ
- South San Francisco, CA, US
Price Chart
- Market Cap
- $36.47M
- P/E
- -0.51
- P/S
- 0.00
- P/B
- -0.17
- EV/EBITDA
- -0.35
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 125.24%
- ROIC
- -149.15%
- Revenue
- $0 · 0.00%
- Net Income
- $-69,163,000 · -34.92%
- EPS
- $-2.16 · -22.73%
- Op Income
- $-70,947,000
- FCF YoY
- -15.46%
- 52W High
- $8.08
- 52W Low
- $0.59
- 50D MA
- $0.99
- 200D MA
- $2.18
- Beta
- 0.10
- Avg Volume
- 1.11M
Get TickerSpark's AI analysis on STSA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 8, 23 | RA CAPITAL MANAGEMENT, L.P. | sell | 30,000 |
| Jun 8, 23 | RA CAPITAL MANAGEMENT, L.P. | sell | 20,000 |
| Jun 8, 23 | RA CAPITAL MANAGEMENT, L.P. | sell | 10,000 |
| Jun 8, 23 | RA CAPITAL MANAGEMENT, L.P. | other | 5,914,252 |
| Jun 8, 23 | O'Neil Thomas P. | sell | 80,000 |
| Jun 8, 23 | O'Neil Thomas P. | sell | 72,340 |
| Jun 8, 23 | O'Neil Thomas P. | sell | 76,595 |
| Jun 6, 23 | O'Neil Thomas P. | other | 13,877 |
| Jun 8, 23 | O'Neil Thomas P. | sell | 190,000 |
| Jun 8, 23 | O'Neil Thomas P. | sell | 60,000 |
Our STSA coverage
Recent articles, reports, and earnings notes.
No research on STSA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate STSA report →Similar companies
Peers in the same neighborhood.